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chronic liver diseases. Its consequences represent a leading cause
of death or of liver transplantation in patients with cirrhosis. Its
pathogenesis mainly originates from an elevation in hepatic vas-
cular resistance to portal blood ﬂow due to structural and
dynamic factors. Structural factors include ﬁbrosis, vascular
remodeling with capillarization of sinusoids, vascular occlusion,
and regenerative nodule formation. The dynamic component is
due to increased hepatic vascular tone, related to reduced bio-
availability of intrahepatic vasodilators, particularly of nitric
oxide, and increased activity of several endogenous vasoconstric-
tors [1]. Secondarily to the increased hepatic vascular resistance,
there is a progressive splanchnic arterial vasodilatation, that
increments portal blood ﬂow, and aggravates and perpetuates
portal hypertension.
In recent years, angiogenesis, a dynamic process leading to the
formation of new vessels from pre-existing blood vessels [2], has
been linked to both intrahepatic and extrahepatic components of
portal hypertension [2,3]. Within the liver, angiogenesis is postu-
lated to contribute to portal hypertension by promoting ﬁbrogen-
esis. Indeed, angiogenesis is a typical feature of liver ﬁbrosis.
Moreover, pharmacologic interventions that inhibit angiogenesis,
especially using receptor tyrosine kinase inhibitors such as
sorafenib or sunitinib, or molecules targeting vascular endothe-
lial growth factor (VEGF) receptor type 2 or Tie2, induce a
decrease in hepatic ﬁbrosis [2]. Outside of the liver, angiogenesis
contributes to the formation of portosystemic collaterals and the
increase in splanchnic blood ﬂow [3]. Portal hypertension is char-
acterized by an extensive network of portosystemic collateral
vessels, which include the esophageal and gastric varices.
Evidence supporting a role for extrahepatic angiogenesis in the
pathogenesis of portal hypertension comprises recent investiga-Journal of Hepatology 20
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VEGF, vascular endothelial growth factor.tions demonstrating that VEGF, a potent angiogenic factor, is
overexpressed in splanchnic organs from portal hypertensive ani-
mals. The expression of VEGF receptor-2 and the endothelial cell
marker CD31 is also increased in the splanchnic territory in
experimental models of portal hypertension. Importantly, block-
ade of VEGF-derived signaling markedly decreases splanchnic
vascularization and portal venous inﬂow in rodent models of por-
tal hypertension [1,3].
In this issue of the Journal of Hepatology, Kaur and colleagues
reported increased levels of circulating endothelial progenitor
cells (EPC) in cirrhosis patients and showed that these cells stim-
ulated angiogenesis in vitro (Fig. 1) [4]. This study represents an
important step forward in the understanding of the pathogenesis
of intrahepatic angiogenesis in cirrhosis and suggests a speciﬁcity
of cirrhotic EPCs.
EPCs are immature precursor cells, smaller than 15 lm that
are detectable in blood and bone marrow [5,6]. They are rare
since their concentration in blood is around 0.005–0.01% of the
white blood cells [5]. In vitro, EPCs are characterized by their abil-
ity to form adherent colonies that proliferate and differentiate
into endothelial lineage. In vivo, they contribute to angiogenesis
within ischemic sites or to vascular repair after vessel wall injury
[6]. Nevertheless, accumulating data demonstrate that these
properties identify a heterogeneous pool of cells with regard to
their origin, differentiation and functional characteristics, as
reviewed elsewhere [5]. In the absence of an unambiguous and
consistent deﬁnition of EPCs, these cells are typically identiﬁed
either by surface antigens using ﬂow cytometry, or by in vitro col-
ony-forming assays. Using ﬂow cytometry, the minimal antigenic
proﬁle should include one or more marker of immaturity (usually
CD34 and/or CD133 in humans; CD34, c-kit, or Sca-1 in mice),
and one or more marker of endothelial commitment (usually
VEGF receptor-2). The alternative approach, i.e., colony formation
in culture, measures not only absolute numbers of EPCs, but also
their overall proliferative capacity and may be more reﬂective of
EPC capacity for endothelial repair.
Kaur and colleagues used both assays and observed higher
circulating EPC levels in chronic liver disease patients without
hepatocellular carcinoma (HCC) than in controls. This increase
was more pronounced in cirrhosis patients and inversely
correlated with prothrombin time. Likewise, another group of12 vol. 57 j 1163–1165
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Fig. 1. Proposed mechanism of endothelial progenitor cells (EPCs) regulation
of angiogenesis in cirrhosis. Cardiovascular risk factors are associated with
reduced circulating EPC levels. Conversely, circulating EPC levels are increased in
cirrhosis patients. EPCs are likely recruited into the liver were they release the
growth factors VEGF and PDGF. This stimulates SEC proliferation and formation of
new vessels in the liver. Whether these new vessels eventually increase or reduce
liver ﬁbrosis and portal hypertension remains to be determined. (Adapted from
Thabut and Shah [2]). EPC, endothelial progenitor cell; HSC, hepatic stellate cell;
PDGF, platelet-derived growth factor; SEC, sinusoidal endothelial cells; VEGF,
vascular endothelial growth factor.
Editorialinvestigators previously found a borderline signiﬁcant increase in
circulating EPC levels in cirrhosis patients without HCC [7]. Inter-
estingly, EPC levels correlated with hepatic venous pressure gra-
dient [7]. Three other studies reported either no difference or
lower circulating EPC levels in cirrhosis patients as compared to
controls [8–10]. Several factors can account for this discrepancy.
First, controls were not matched for cardio-vascular risk factors
in any of the above mentioned studies. It limits the interpretation
of the results since absolute number and functional capacity of
EPCs are reduced in individuals with diabetes, smoking, arterial
hypertension, hypercholesterolemia, obesity or aging [5,6]. Some
of these risk factors, such as diabetes and smoking, are frequent
in cirrhosis patients and may mask the impact of cirrhosis on
EPC levels. For instance, in the study by Chen and colleagues,
52% and 31% of cirrhosis patients were smokers and had diabetes,
respectively. This prevalence was not mentioned in controls but
we can assume that it was lower [8]. Second, these three studies
likely suffer from a limitation in power since they included only
10–16 cirrhosis patients without HCC [8–10]. HCC patients
should be analyzed separately as HCC is associated with an
increase in circulating EPC levels [7,9,11]. Third, these studies
did not mention the severity of cirrhosis in patients without
HCC, while circulating EPC levels seem to be increased primarily
in advanced cirrhosis patients [8–10]. Altogether, these data sug-
gest that circulating EPC levels are increased in patients with
advanced cirrhosis. Their potential interest as biomarkers of1164 Journal of Hepatology 2012ﬁbrosis and/or portal hypertension remains to be assessed in
large cohorts of patients with controls matched for cardiovascu-
lar risk factors.
The mechanism responsible for this increase in circulating
EPCs levels in cirrhosis is unknown. If acute ischemia generally
increases circulating EPC levels, reduced levels and/or function
are reported in patients with chronic cardiovascular diseases,
such as stable coronary artery disease, congestive heart failure,
cerebrovascular disease, transplant vasculopathy or stent reste-
nosis [6]. This suggests that chronic liver ischemia potentially
associated with cirrhosis may not account for elevated circulat-
ing EPC levels in cirrhosis [12]. Mobilization of EPCs depends
on the nitric oxide-dependent upregulation of matrix metallo-
proteinase-9 expression by bone marrow stromal cells [13]. A
large body of evidence unmasks extrahepatic overproduction
of nitric oxide as one of the hallmarks of cirrhosis [14]. We
can speculate that this high nitric oxide production could
contribute to EPC mobilization and to elevated EPC levels in
cirrhosis.
Kaur and colleagues demonstrated that circulating EPCs from
cirrhosis patients stimulated proliferation of sinusoidal endothe-
lial cells and their organization in tubular structures. This effect
was dependent upon the release by cirrhotic EPCs of two proan-
giogenic growth factors: platelet-derived growth factor and
VEGF. Given the above mentioned postulated contribution of
hepatic angiogenesis to ﬁbrogenesis, the authors suggested that
circulating EPCs may contribute to cirrhosis progression and its
complications. In contrast, several previous studies demonstrated
that injection of healthy rat EPCs into cirrhosis rats decreased
liver ﬁbrosis and inﬂammation, increased hepatocyte prolifera-
tion and improved liver function [15–18]. Importantly, EPC injec-
tion also induced intrahepatic angiogenesis, decreased portal
pressure and increased hepatic blood ﬂow [16]. If these data con-
ﬁrm the proangiogenic effect of EPCs in the cirrhotic liver, they
question the view that liver angiogenesis induced by EPCs con-
tributes to ﬁbrosis and portal hypertension. Two hypotheses
can reconcile these observations. First, the effect of EPCs on liver
ﬁbrosis and portal hypertension may depend upon their source.
Kaur and colleagues found a two to threefold higher proangio-
genic activity with circulating EPCs from cirrhosis patients than
from healthy controls [4]. All studies reporting a favorable effect
of EPC transplantation used EPCs derived from the bone marrow
of healthy rats. This suggests that the proangiogenic activity of
cirrhotic EPCs may be excessive and induce the formation of
abnormal vessels, thus worsening liver ﬁbrosis and portal hyper-
tension. Alternatively, liver angiogenesis induced by cirrhotic
EPCs may be beneﬁcial and the increase in EPC levels in cirrhosis
may be a compensatory mechanism. In support of this statement,
EPC are generally implicated in repair to injury response [6].
Moreover, new intrahepatic vessels could theoretically act as por-
tal hypertension decompressing shunts [2]. Finally, beside the
studies mentioned above showing that therapeutic approaches
targeting aberrant vasculature structure in cirrhosis could have
a beneﬁcial effect on portal hypertension, few others did not.
For example, in a study performed using two complementary
models of cirrhosis, the administration of cilengitide, an inhibitor
of the avb3 integrin that plays an important role in liver angio-
genesis, promoted hepatic ﬁbrosis and inﬂammation despite its
anti-angiogenic effects [19]. Assessing the effect of the transplan-
tation of cirrhotic EPCs into cirrhosis rats would help determine
the correct hypothesis.vol. 57 j 1163–1165
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In conclusion, this study not only highlights a newmechanism
for intrahepatic angiogenesis but also provides new prospects.
The proangiogenic effect of EPCs in cirrhosis may not be
restricted to liver sinusoidal endothelial cells. EPCs may also con-
tribute to splanchnic angiogenesis, which plays a role in the
development and maintenance of splanchnic hyperemia in portal
hypertension [1]. Moreover, in different population of subjects,
circulating EPC levels correlated with endothelial function
[5,20]. Whether EPC could contribute to the arterial vasodilation
associated with portal hypertension in cirrhosis patients remains
to be determined. Further studies are thus needed to delineate
how EPCs may modulate portal hypertension.Financial support
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